NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/08/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization69.29 mln
Float5.45 mln
Earnings Date05/06/2026
EPS
2.57
Solid
P / E
3.25
Deeply undervalued
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
17.14
Highly suspicious
1-Year Forecast
9.33
Modest upside
Relative Strength
99
/ 100
Top performer
Business Description
Founded in 2012 and based in Thousand Oaks, California, Atara Biotherapeutics is a clinical-stage company working to create new treatment options for patients with cancer and immune system disorders. Its most advanced program, tabelecleucel, uses the body's own immune cells to fight diseases caused by the Epstein-Barr virus, including a serious condition that can develop after organ or stem cell transplants. The company is also advancing a next-generation cell therapy aimed at certain blood cancers and autoimmune conditions, and conducts its research in partnership with two leading medical institutions.
